Welcome to our dedicated page for Regulus Therapeu SEC filings (Ticker: RGLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regulus Therapeutics Inc. filings document the public-company record of a biopharmaceutical issuer focused on microRNA-targeted medicines and its completed transition out of Nasdaq-listed reporting status. Recent filings include an 8-K reporting completion of an acquisition transaction involving Novartis AG, a Form 25 covering removal of Regulus common stock from Nasdaq listing and registration, and a Form 15 covering termination or suspension of Exchange Act reporting duties for its common stock.
The filing record also identifies the RGLS common stock class, capital-structure status, material-event reporting, exchange-listing matters and deregistration mechanics. These disclosures frame Regulus as a former reporting issuer whose regulatory documents now primarily record corporate-status changes after its biopharmaceutical development activity.
Novartis AG, through its wholly-owned subsidiary Redwood Merger Sub Inc., has filed Amendment No. 2 to its Schedule TO for the pending acquisition of Regulus Therapeutics Inc. (NASDAQ: RGLS). The tender offer terms remain unchanged at $7.00 in cash per share plus one contingent value right (CVR) that could deliver an additional $7.00 in cash upon achievement of a specified milestone.
The key update disclosed in this amendment is regulatory: the waiting period under the Hart-Scott-Rodino (HSR) Act expired on 20 June 2025 at 11:59 p.m. ET. With U.S. antitrust clearance now obtained, one of the principal conditions to closing has been satisfied. The offer, launched on 27 May 2025, remains subject to the other conditions detailed in the Offer to Purchase, including the minimum tender condition and customary closing requirements.
Item 12 adds Exhibit (a)(5)(E), a press release issued by Novartis on 23 June 2025 announcing the HSR status. No other economic terms, timelines, or financial metrics have been modified. Signatures from Novartis representatives and Redwood Merger Sub certify the accuracy of the filing.
- Transaction structure: all-cash tender offer followed by a merger; CVR provides additional upside.
- Regulatory status: HSR clearance achieved; remaining approvals not specified as material hurdles in this amendment.
- Next steps: shareholders may continue to tender shares; completion depends on remaining conditions outlined in Section 15 “Conditions to the Offer.”